Stem cell transplant shows promise against rare blood cancer in new trial
NCT ID NCT02844361
First seen Feb 12, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This study tested whether a stem cell transplant (using the patient's own cells) could help people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer, live longer compared to standard chemotherapy. The trial involved 70 adults in China who had not received standard treatment. While the transplant may control the disease better, patients typically need ongoing monitoring and medication, so this is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.